QLS1410
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
May 23, 2026
QLS1410 in Participants With Uncontrolled Hypertension
(clinicaltrials.gov)
- P2 | N=260 | Enrolling by invitation | Sponsor: Qilu Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation
Enrollment open • Cardiovascular • Hypertension
April 25, 2026
Study of QLS1410 in the Treatment of Primary Aldosteronism.
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P2 trial • Endocrine Disorders
March 25, 2026
QLS1410 in Participants With Uncontrolled Hypertension
(clinicaltrials.gov)
- P2 | N=260 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P2 trial • Cardiovascular • Hypertension
January 23, 2026
A Food Effect Study of QLS1410 in Healthy Chinese Adults
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P1 trial • Cardiovascular • Hypertension
September 04, 2025
A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension
(clinicaltrials.gov)
- P1 | N=78 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P1 trial • Cardiovascular • Hypertension
1 to 5
Of
5
Go to page
1